Companies
Bio-Techne
Life sciences toolsMinneapolis, MinnesotaTECHAbout 3,000 employees
More about Bio-Techne
Maker of research reagents, proteins, antibodies, spatial biology and diagnostic products for life science researchers and labs
Revenue
$1.22B
Fiscal 2026 (year to June), roughly flat
Employees
About 3,000
As of June 2026
Stock
TECH
Nasdaq
Headquarters
Minneapolis, Minnesota
CEO
Kim Kelderman
Since February 2024
Main businessesProtein Sciences, Diagnostics and Spatial Biology
Current strategyAgreed in June 2026 to be acquired by Merck KGaA, Darmstadt, Germany; shareholders approved the deal in September 2026 and it awaits other closing conditions
CompetitorsThermo Fisher Scientific, Revvity, Abcam
Related companiesThermo Fisher ScientificRevvityDanaher
Checked October 11, 2026 · Sources: sec.gov, sec.gov (2), sec.gov (3)
No source-backed updates for Bio-Techne yet. They appear here when a public report or filing covers the company.
No one has posted about Bio-Techne yet. Be the first to post ›
Follow Bio-Techne in a feed reader, no account needed: RSS feed